Plant · Scientific monograph
Withania somnifera
Ashwagandha / Indian winter cherry
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Stress Response Research, Stress & Anxiety Research, Neurological & Cognitive Research, Endocrine Research
Research overview
Historical use
Withania somnifera (Ashwagandha) has been a cornerstone of Ayurvedic medicine for over 3,000 years, classified as a 'rasayana' (rejuvenating tonic) and 'balya' (strength-promoting). Its Latin species name 'somnifera' (sleep-inducing) reflects its traditional use as a sedative and anxiolytic. Historical texts describe its use for debility, emaciation, nervous exhaustion, and as an aphrodisiac. The Sanskrit name 'Ashwagandha' (smell of horse) refers both to the root's odour and the traditional belief that it confers equine strength.
Modern research context
Ashwagandha is one of the most clinically investigated adaptogens in modern phytomedicine. A 2026 randomised trial demonstrates significant reductions in anxiety scores and cortisol levels in patients with stress, anxiety, and hypertension [3]. An 8-week RCT confirms improvements in VO2max and reduced exercise-induced fatigue at low doses [4], and a 2026 study shows improvements in quality of life and sleep parameters in elderly adults [5]. Ashwagandha modulates the HPA and HPG axes with documented relevance for PCOS and PMS through hormonal normalisation [6]. Its multi-targeted monoaminergic and neurotrophic mechanisms support a role as a novel antidepressant supplement [9].
Adverse effects
A 2026 critical review of preclinical and clinical evidence documents gastrointestinal effects (nausea, diarrhoea), sedation, and hepatic adverse effects as primary adverse effects of clinical concern [7]. Thyroid hormone elevation has been reported in susceptible individuals, particularly those with pre-existing thyroid dysfunction [8]. Sedation and drowsiness are expected at higher doses given GABAergic mechanisms. Rare but serious adverse events include drug-induced liver injury (DILI) — multiple case reports of hepatotoxicity requiring medical attention have been documented [7]. Long-term safety data beyond 12 weeks are limited.
Contraindications
Contraindicated in patients with autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis) due to potential immune stimulation. Contraindicated in thyroid disease or concurrent thyroid medication use given documented thyroid hormone modulation [8]. Avoid with barbiturates, benzodiazepines, and other CNS depressants due to additive sedation [2]. Caution with immunosuppressants. Contraindicated in pregnancy (traditional abortifacient). Caution with CYP450-metabolised drugs [2].
Clinical and phytochemical data
Used part
Root (primary); leaf extract (secondary, higher withanolide concentration)
Primary active compounds
Withanolide A, B, D (steroidal lactones)
Withaferin A (steroidal lactone — highest bioactivity)
Withanosides IV and V (sitoindosides)
Alkaloids: withanine, somniferine, anaferine
Withanolide glycosides (withasomniferols A, B, C)
Iron and amino acids (free radical scavengers)
Mechanism of action
Ashwagandha exerts adaptogenic effects primarily through modulation of the HPA (hypothalamic-pituitary-adrenal) axis, reducing serum cortisol levels and blunting the stress response — a mechanism confirmed in a 2026 clinical trial [3]. Withanolides bind to and modulate GABA-A receptors, producing anxiolytic and sedative effects without significant respiratory depression [2]. Multi-targeted antidepressant activity converges on serotonergic, dopaminergic, and noradrenergic neurotransmitter systems alongside suppression of NF-κB-driven neuroinflammation [9]. Withania somnifera modulates thyroid hormone synthesis — regulating T3 and T4 levels — through upregulation of thyroid-specific gene expression [8]. Immune-modulatory effects are mediated through Th1/Th2 balance and NK cell activation, relevant to oncological applications [1].
Pharmacokinetics
Absorption
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Oral bioavailability of withanolides, particularly Withaferin A, is limited by poor aqueous solubility and significant first-pass hepatic metabolism. Lipid-based formulations and black pepper (piperine) co-administration are used commercially to enhance absorption, though formal human bioavailability studies with standardised extracts are lacking.
Distribution
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Withanolides are lipophilic and distribute to CNS, adrenal, and reproductive tissues in animal models, consistent with the observed HPA axis modulation and hormonal effects [6]. Plasma protein binding and volume of distribution in humans have not been formally characterised.
Metabolism
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Withania somnifera extracts interact with cytochrome P450 enzymes; a 2026 safety review specifically identifies CYP450 interactions as a documented concern for herb-drug interactions in clinical practice [2]. The specific isoforms involved and degree of inhibition or induction have not been characterised in standardised human in vivo studies.
Excretion
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Elimination routes and half-life of withanolides in humans are not established in published clinical pharmacokinetic studies. Phase II hepatic conjugation followed by renal excretion is expected based on structural characteristics of the steroidal lactone backbone.
Safety and interactions
Drug interactions
CNS depressants (benzodiazepines, barbiturates, opioids, alcohol): Additive sedation through shared GABAergic mechanism; combination requires caution and dose reduction of the depressant agent [2]. CYP450 substrates: Ashwagandha extracts are documented to interact with cytochrome P450 enzymes, potentially altering plasma levels of co-administered drugs metabolised by CYP pathways [2]. Thyroid medications (levothyroxine, antithyroid drugs): Withania somnifera modulates T3/T4 synthesis and gene expression [8]; combination with thyroid medications may produce unpredictable hormonal effects requiring monitoring. Immunosuppressants (tacrolimus, cyclosporine): Potential immune-stimulating activity may antagonise immunosuppressive therapy. Antihypertensives: Additive blood pressure-lowering effects observed in a 2026 RCT in hypertensive patients [3].
Toxicity
A 2026 comprehensive adverse effects review documents hepatotoxicity as the most clinically serious risk — multiple case reports of drug-induced liver injury (DILI) including acute hepatitis have been attributed to Ashwagandha, predominantly at high doses or with prolonged use [7]. GI effects (nausea, diarrhoea) are the most common adverse events in RCTs. Thyroid hormone elevation, including reports of hyperthyroidism, is a documented endocrine risk [7, 8]. LD50 data in humans are not established; standardised extract doses of 300-600 mg/day are generally well tolerated in short-term (8-12 week) clinical trials [3, 4].
Special precautions
Pregnancy
Contraindicated. Ashwagandha is a traditional abortifacient; uterotonic alkaloids are present in the root. Avoid throughout pregnancy.
Lactation
Withanolide excretion into breast milk has not been characterised. Medicinal-dose use during lactation is not recommended due to insufficient clinical safety data and the potential for hormonal effects from withanolide activity.
Hepatic impairment
Hepatotoxicity risk is documented [7]; CYP450-dependent metabolism is hepatically expressed [2]. Contraindicated in patients with active hepatic disease. Liver function monitoring is strongly advisable in all patients using Ashwagandha beyond 8 weeks.
Renal impairment
No formal studies in renal impairment. Conjugated withanolide metabolites are renally excreted. Use with caution in severe renal impairment and monitor.
Sources and references
- [1] - Bertollo AG, Spohr L, Bearzi AE et al., "Medicinal Plants for Major Depressive Disorder", Brain Sciences, 2026, PMID: 41750223
- [2] - Caus MN, Lupoae M, Chitescu CL, "Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action", Pharmaceuticals, 2026, PMID: 41901246
- [3] - Pattojoshi A, Kumar Patra S, Idrees SA et al., "Safety and efficacy of ashwagandha in stress and anxiety with hypertension and associated cardiometabolic risk factors", Stress, 2026, PMID: 42105298
- [4] - Prajapati H, Satia M, Shah D et al., "Efficacy and Safety of Low-Dose Ashwagandha Supplementation on Exercise Endurance", Phytotherapy Research, 2026, PMID: 41846233
- [5] - Honnutagi R, Ingale A, Naikawdi A, "Ashwagandha Root Extract Improves General Health in Elderly Men and Women", Phytotherapy Research, 2026, PMID: 41725116
- [6] - Namysl M, Matczak S, Dachowska S et al., "Withania somnifera in Women's Hormonal Modulation: Implications for PCOS and PMS", Cureus, 2026, PMID: 41694897
- [7] - Kumar A, Sah BK, Ahmad F et al., "Potential Adverse Effects of Ashwagandha: A Critical Review of Preclinical and Clinical Evidence", Phytotherapy Research, 2026, PMID: 41502355
- [8] - Hossain MS, Shuvo MSP, Talukder MMH et al., "Withania somnifera Root Extract Ameliorates PTU-Induced Hypothyroidism by Regulating Hormone Levels and Gene Expression", Food Science & Nutrition, 2026, PMID: 42005335
- [9] - Li X, Li X, Li Y et al., "Rhodiola rosea, Ginkgo biloba, and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways", Frontiers in Nutrition, 2026, PMID: 41909050